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Abstract Kinases are key enzymes involved in deregulated
signal transduction associated with cancer development and
progression. The advent of personalized medicine drives
the development of new diagnostic tools for patient
stratification and therapy selection Ginsburg and Willard
(Transl Res 154:277-287, 2009). Since deregulation of
kinase-mediated signal transduction is implied in tumori-
genesis, the analysis of all kinases (the kinome) active in a
particular tumor may yield tumor-specific information on
aberrant cell signalling pathways. Tumor tissue kinase
activity profiles may correlate with response to therapy
and therefore may be used for future therapy selection. In
this Trend paper we describe peptide array and mass
spectrometry-based technologies and new developments
for kinome profiling, and we present an outlook towards
future implementation of therapy selection based on kinome
profiling in clinical practice.
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Introduction
Kinases are key enzymes involved in deregulated signal
transduction associated with cancer development and
progression. The advent of personalized medicine drives
the development of new diagnostic tools for patient
stratification and therapy selection [1]. Since deregulation
of kinase-mediated signal transduction is implied in
tumorigenesis, the analysis of all kinases (the kinome)
active in a particular tumor may yield tumor-specific
information on aberrant cell signalling pathways. Tumor
tissue kinase activity profiles may correlate with response
to therapy and therefore may be used for future therapy
selection. In this paper we describe peptide array and mass
spectrometry-based technologies and new developments for
kinome profiling, and we present an outlook towards future
implementation of therapy selection based on kinome
profiling in clinical practice.
Protein kinases
The human kinome
Phosphorylation and dephosphorylation are the central
mechanism for intra- and intercellular signal transduc-
tion. Kinases are key enzymes catalyzing protein phos-
phorylation by transferring a phosphate group from
adenosine triphosphate (ATP) to specific substrates. In
the human genome 518 protein kinases have been
identified, of which 90 are tyrosine kinases [2]. Dereg-
ulation of kinase activity by gene amplification or
mutations has been implicated in cancer and immune
system diseases as well as in metabolic and infectious
diseases. Virtually all cellular signalling processes involve
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transfer of phosphate groups, implying that inhibition of
aberrant kinase activity can repair deregulated cellular
signalling. Therefore, kinases and especially tyrosine
kinases have become one of the most intensively targeted
enzyme classes for therapy, illustrated by the development
of numerous small-molecule inhibitors for the treatment of
cancer by the pharmaceutical industry.
Protein kinases
Protein kinases catalyze the transfer of the γ-phosphate of
ATP to a serine (Ser), threonine (Thr), or tyrosine (Tyr)
residue of the target protein. Kinases have an active site
where ATP is bound by hydrogen bonds to the adenine
moiety. An Mg2+ ion is required at the active site for
phosphotransfer to occur. ATP binding takes place in the
so-called hinge region of the kinase connecting the N-
terminal and C-terminal domains [3]. In the hinge region
kinases have a conserved activation loop whose degree of
phosphorylation is highly correlated with catalytic activity
[4]. Most kinase inhibitors are ATP mimics that bind
competitively in the ATP binding cleft, mimicking the
adenine hydrogen-bonding network [3]. Several kinase
inhibitor classes can be distinguished: type 1 inhibitors
bind the kinase with the activation loop in the active
conformation, whereas type 2 inhibitors bind the kinase
with the activation loop in the inactive conformation. A
third class of inhibitors binds outside the ATP binding site
to modulate kinase activity (allosteric inhibitors). The
fourth class of inhibitors is formed by irreversible or
covalent inhibitors targeting an active site cysteine residue
present in a subgroup of kinases [3].
Kinases and cancer
Many kinases have been associated with tumor cell
proliferation, migration, and survival [5]. Some kinases
have gained transforming capability by gene amplification,
mutation, or translocation and are considered to be
oncogenic [6]. Their constitutive activity is essential for
cancer cell survival or proliferation. Inhibition of these
oncogene-addicted cells by small-molecule inhibitors has
proven very effective for the treatment of selected tumor
types. Examples of oncogenic kinases are BCR–ABL1
fusion protein in chronic myelogenous leukemia (CML)
[7], PI3KCA in cervical cancer [8], and the V600E
mutation in the activation loop of BRAF involved in
development of melanoma and ovary, thyroid, colon, and
pancreatic carcinomas [9]. Other non-oncogenic or mutated
kinases are required for cell growth, cell division, and/or
proliferation, and are often found downstream of trans-
forming oncogenes. Examples of these kinases are MEK1,
MEK2 , mTOR, RSK, FGF, and CDKs. Other protein
kinases are involved in auxiliary processes for tumor
maintenance and survival, e.g., for new blood vessel
formation mediated by vascular endothelial growth factor
receptor (VEGFR).
Kinases and anticancer treatment
In the past decade, multiple agents that target specific
signalling proteins important for tumor growth have been
developed and reached clinical approval, thereby impor-
tantly extending the therapeutic arsenal for patients with
advanced (inoperable or metastasized) cancer. In tumors
where the oncogenic kinase driver genes are known,
selective small-molecule inhibitors of the deregulated
kinase have significant impact. The most well-known
example is the BCR–ABL1 fusion protein, the causative
transforming event in chronic myelogenous leukemia.
Upon treatment with imatinib up to 80% response rates in
CML patients have been reported [10].
Additionally, inhibitors of angiogenic receptor tyrosine
kinases have been developed as a systemic treatment
strategy for cancer. These agents target the formation of
new blood vessels required for tumor growth and the
formation of metastases, a process called angiogenesis. The
small-molecule tyrosine kinase inhibitors (TKIs) sunitinib
and sorafenib target multiple tyrosine kinase receptors,
including VEGFR and platelet-derived growth factor
receptor (PDGFR), and have demonstrated clinical benefit
in patients with advanced renal cell carcinoma [11, 12].
Compared with previous standard therapy, these agents
doubled progression-free survival and increased response
rates from 5–10 to 30%, with durable disease regression in
individual patients. Moreover, sunitinib has been approved
for the treatment of gastrointestinal stromal tumor (GIST)
after disease progression or intolerance to imatinib [13]. In
addition to tyrosine kinase inhibition, sorafenib was
originally developed as a Raf serine/threonine kinase
inhibitor and has been approved for the treatment of
hepatocellular cancer [14].
Other clinically approved TKIs include erlotinib,
which targets epidermal growth factor receptor (EGFR),
for the treatment of advanced non-small cell lung cancer,
and lapatinib, a dual EGFR (ErbB1) and HER2/Neu
(ErbB2) inhibitor, for the treatment of metastatic breast
cancer. Numerous clinical trials are ongoing with these
and other TKIs in various cancer types, both as single
agents and in combination with other targeted agents or
chemotherapy.
Although small-molecule TKIs have dramatically im-
proved therapy in a selection of advanced cancer patients,
only a subgroup of patients will actually benefit from these
agents. A significant proportion of patients will not respond
to targeted treatment, demonstrating initial resistance. In
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addition, tumor regression and clinical improvement are
temporary phenomena as well, as most patients will
eventually acquire resistance [15] and subsequently expe-
rience disease progression.
In this paper we discuss strategies for kinase activity
profiling to acquire new insights into molecular mecha-
nisms of drug resistance and response to therapy and
with potential for accomplishing treatment selection in
patients.
Kinome profiling
Global kinome analysis
Kinome profiling or ‘kinomics’ [16] is the global analysis
of all kinases in cells or tissue with respect to abundance,
activity, substrate specificity, phosphorylation pattern, and
mutational status. Several strategies can be followed
including the chemical proteomics approach for kinase
abundance and phosphorylation analysis, large-scale
(>300 kinases) analysis of recombinant kinases [17, 18]
for substrate specificity analysis, peptide substrate arrays
for upstream kinase activity profiling, and qPCR for
mutational analysis. In this paper, we will focus on the
emerging strategies for protein-level kinome profiling
using chemical proteomics, reverse protein arrays with
immunoassay readout, and peptide substrate arrays (Fig. 1,
Table 1).
Chemical proteomics for TKI target identification and
kinome profiling
Conventionally, small-molecule kinase inhibitors are tested
against a panel of recombinant kinases to identify drug
targets and to assess inhibitor specificity and selectivity
[16]. However, these in vitro assays include only a subset
of all protein kinases and do not take into account
physiological kinase binding partners, post-translational
modifications, mutated forms, cellular concentrations, or
compartmentalization.
Chemical proteomics is emerging as a novel compre-
hensive kinome-wide strategy for drug target identifica-
tion in disease-relevant cells and tissues. Chemical
proteomics is an enrichment strategy that combines an
immobilized drug affinity pull-down approach with
mass spectrometry-based proteomics for protein identi-
fication, quantification, and phosphorylation analysis
(for recent reviews, see [19, 20]). A suitable broad
specificity ATP-competitive protein kinase inhibitor such
as purvalanol B, bisindolyl maleimide, and staurosporine
or more specific inhibitors such as imatinib or dasatinib
are covalently immobilized on a biocompatible matrix
such as sepharose or agarose through a free hydroxyl,
carboxyl, sulfhydryl, or primary amine group present on
the inhibitor. If the inhibitor does not have a linkable
group, an analogue must be synthesized containing a
linkable moiety to confirm the inhibitory activity of the
analogue. The group used for immobilization should not
interfere with binding of the inhibitor to the kinase. Cell
lysates, consisting of proteins in their native state, are
incubated with the affinity matrix and washed extensively
prior to elution to reduce protein background. Bound
proteins are eluted and identified by using nanoLC–MS/
MS-based proteomics (Fig. 2). When focusing on
phosphopeptide identification, a phosphopeptide enrich-
ment step can be applied by using immobilized metal ion
affinity chromatography (IMAC) or titanium dioxide
beads prior to LC–MS/MS [21]. The main advantages
of chemical proteomics over conventional methods are:
(1) it provides an unbiased method for finding drug-
interacting proteins; (2) the method is applicable to
protein kinases in their native cellular environment, (3)
at natural abundances, and (4) in the presence of in vivo
interaction partners; and (5) post-translationally modified
forms, splice variants, and mutated forms are also
captured. Successful examples of chemical proteomics
pull-downs employing immobilized TKIs dasatinib, ima-
tinib, and nilotinib show that dasatinib inhibits the Tec
kinases Btk and Tec at nanomolar concentrations but not
Ltk, in addition to its target ABL and SRC kinases [22].
For the highly specific TKI nilotinib DDR1 was identi-
fied as additional major target and NQO2 as off-target
[23], showing the power of chemical proteomics for TKI
target and off-target identification.
A drawback of chemical proteomic approaches has
been the high amount of required input material, tens of
milligrams of total protein. However, recently, scaling
down to the 2–8 mg protein level has been demonstrated
[24], opening up the chemical proteomics approach for a
much wider range of applications. Further streamlining the
chemical proteomics workflow allowed Fernbach et al. to
identify 40 bosutinib-interacting proteins from as little as
2×106 K562 cells, which is equivalent to ∼0.5 mg protein
[25]. Most likely the near future will see further
miniaturization of methods, e.g., with magnetic bead-
assisted pull-downs. Another complicating factor is the
presence of abundant, sticky proteins that may obscure
detection of low-abundance kinases. Bead control experi-
ments can be performed but most of the time interference
can be attributed to (usually) high-abundant proteins that
bind aspecifically to the hydrophobic inhibitors with
medium affinity. Optimization of wash stringency is
important for optimal detection of kinases. However,
non-kinase ATP-binding proteins will always be ob-
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served in the immobilized kinase pull-downs, and the
same holds for kinase-binding proteins (secondary and
ternary binders). For comprehensive reviews discussing
chemical proteomics for (off-)target identification, see
[19, 20].
Chemical proteomics for kinome profiling
To profile the kinome comprehensively, a mixture of
immobilized inhibitors must be formulated such that all
kinases expressed by a cell are quantitatively captured.
Table 1 Comparison of methods for kinase (activity) profiling
Method Characteristic(s) Information content Kinase activity Detection Throughput
Array-based
Peptide array (PepScan) In vitro Medium (1,000 peptides) Yes (indirect) Radiolabeling High
Peptide array (PamGene) In vitro Low (144 peptides) Yes (indirect) Ab-based High
Protein array (Zeptosens) Targeted, in vivo Low (∼100 p-proteins) Yes (direct) Ab-based Medium
MS-based
Kinobead-based profiling Unbiased, in vivo High (1,000s peptides) Yes
(+phosphoproteomics)
MS/MS Low
KAYAK approach In vitro Low (∼100 peptides) Yes (indirect) MS/MS Medium
MRM-based kinome profilinga Targeted, in vivo Medium (∼500 peptides) Yes (direct) MS/MS Medium
KAYAK kinase activity assay for kinome profiling, MRM multiple reaction monitoring, Ab antibody
a Anticipated method for the human kinome; a kinome-wide MRM-based analysis has been reported for yeast [43]
Fig. 1 Overview of kinome
profiling approaches. Tumor bi-
opsy material can be profiled by
chemical proteomics yielding
kinase abundances, along with
associated signalling complexes
and phosphorylation sites.
Kinases that are differential for
responders vs. non-responders
to therapy can be used to design
custom substrate peptide arrays
or reverse protein arrays. These
custom arrays can be used,
when validated, for therapy se-
lection in the clinic
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Broad-spectrum inhibitors should be combined with more
specific inhibitors in order to capture the kinases present in
cell lysate. In this respect kinome profiling by chemical
proteomics differs from drug target identification, where a
single immobilized target inhibitor is employed. For
quantitative analysis of kinase abundance and phosphory-
lation levels several quantitative chemical proteomics
approaches have been reported recently. Bantscheff et al.
demonstrated in a seminal paper the application of
kinobeads, a mixture of seven immobilized protein kinase
inhibitors, combined with isobaric tags for relative and
absolute quantitation (iTRAQ) for quantitative proteomic
analysis of protein kinases [26]. In a competition assay with
clinically relevant free kinase inhibitors the known cellular
targets of imatinib were identified, i.e., BCR–ABL1, but
also unexpected binders DDR1 and NQO2. The method
yielded kinome-wide affinity constants for imatinib and
identified known targets as well as novel off-targets [26].
Additionally, the paper reported a total of 307 distinct
protein kinases (296 human and 196 rodent) from 14
human and rodent cell lines and tissues [26]. In addition to
kinome profiles, downstream pathway information was also
obtained including specific phosphorylation site information
of kinases and kinase targets. Both kinases as well as kinase-
binding proteins are captured, which is a plus for pathway
discovery. A recent state-of-the art chemical proteomics
study applied a quantitative analysis of the interactome of
immobilized staurosporine analogue K252A. By
preincubating cell lysate with soluble inhibitors, true binders
were distinguished from aspecific binders [24]. A specific
variation of chemical proteomics is activity-based profiling.
The kinase-binding ligand (without solid matrix) is linked to
a (photo)reactive cross-linker group to form a covalent bond
with the interacting protein upon binding. A biotin group is
also included in the structure to enable selective capture of
the ligand–kinase complex by streptavidin [27, 28].
Kinome profiling combined with phosphoproteomics
In addition to the presence (identification and quantitation)
of kinases, their regulation and catalytic activity are
relevant for their in vivo functions. Recently, combined
chemical and phosphoproteomic methods have been used to
characterize the activity of dasatinib in lung cancer [29].
Fig. 2 Chemical proteomics workflow. A small-molecule kinase
inhibitor is covalently linked to a resin. Lysate is incubated with the
immobilized inhibitor, washed and bound proteins are eluted. Eluted
proteins are identified and quantified by LC–MS/MS yielding kinase
abundances, phosphorylation sites, and interacting proteins
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Regulatory phosphorylation sites are of importance for in
vivo function of kinases and many kinase phosphorylation
sites have been reported [30–32]. Even more relevant is the
activation loop phosphorylation level which can be used as
a surrogate readout for in vivo kinase activity. Oppermann
et al. recently performed large-scale quantitative proteomics
analysis of three different cancer cell lines by using three
immobilized kinase inhibitors yielding quantitative kinase
measurements of 170 different kinases. Additionally, the
ATP-competitive VI16832 ligand was used in a pull-down
for phosphopeptide analysis yielding 1,200 distinct phos-
phorylation sites on 200 kinases, including more than 50
activation loop phosphopeptides [21].
Finally, the above studies show that kinase-selective
isolation combined with various proteomics strategies opens
a detection window for low-abundance kinases. We envision
that correlating kinase abundance, associated protein com-
plexes, and phosphorylation patterns in patient material to
therapeutic efficacy and prognosis will be key for develop-
ment of novel diagnostics tests for patient stratification. These
novel tests may be MRM mass spectrometry-based or,
alternatively, may make use of phosphorylation-specific
antibodies against key phosphorylation sites or key peptide
substrates to be implemented in measurements employing
reverse protein arrays of peptide arrays (see below).
Reverse protein arrays
Phosphorylation site-specific antibodies can be used to
detect (activated) kinases or kinase substrates in active
signalling pathways. These phosphorylation site-specific
antibodies combined with western blotting are the classical
tools for pathway analysis. A parallel high-sensitivity
reverse protein array format using phosphorylation site-
specific antibodies has been developed by the company
Zeptosens [33]. Tissue or cell lysates (1×105 cells) are
spotted in an array format on a high-adsorbance chip
surface, blocked, and incubated with antibodies. The
fluorescence readout makes use of planar waveguide
technology to selectively measure target-bound antibodies
with very low background signal. In a proof of principle
paper Weissenstein et al. reported sensitivities (LOD) of
33 pg/ml for plasminogen activator inhibitor-1, 1 pg/ml for
VEGF, and 1 pg/ml urokinase-type plasminogen activator
in breast tumor extracts [34]. Recently, reverse arrays have
been applied to analyze the effect of succinate signalling
via receptor GPR91 on dendritic cells. For pathway
analysis the reversed array was probed by phospho-
specific antibodies against Erk1/2, Mek1 and Mek2,
STAT1, STAT2, STAT3, STAT5, STAT6, and P38 [35].
Sensitivity of the Zeptosens platform is compatible with
tumor core biopsies [34] and can yield cancer-relevant
pathway coverage depending on availability of high-quality
phospho-specific antibodies. Currently, antibodies against
109 different target proteins are available with a total of 98
different phosphorylation sites covered.
Kinase peptide substrate arrays
Microarrays of kinase substrate peptides have been developed
to study (recombinant) kinase specificity and potentially
cellular signal transduction by detecting up- and down-
regulation of peptide phosphorylation in an array-based
format. By generating information on kinase-induced peptide
phosphorylation, these arrays may provide new insights into
specific downstream signalling pathways, e.g., involved in
proliferation and migration of tumor cells, and identify
potential druggable targets. Ideally, kinase peptide substrate
arrays provide kinase activity values across the kinome.
Originally, these arrays were used to determine the substrate
specificity pattern of individual kinases, and later to determine
kinase activity in complex mixtures such as cell lysates and
tissues [36]. Kinase peptide substrate arrays consist of
immobilized peptides containing Ser, Thr, and Tyr residues
with additional sequence context for phosphorylation by
their upstream kinases and can therefore reveal kinase
activity in vitro (Fig. 3). Commercially available peptide
arrays (e.g., PepChip, PamChip) contain typically between
144 and ∼1,200 peptides with Ser, Thr, or Tyr residues
available for phosphorylation and additional amino acid
sequence context. Peptide sequences are derived from
literature or computational predictions and are correlated
with one or multiple upstream kinases. After incubating the
array with cell lysate, phosphorylation is determined by
phosphoimaging (radioactive [33P]ATP) or fluorescence
microscopy (anti-phospho antibodies). Advantages of pep-
tide arrays include parallel readout of up to 3,000 spots,
requirement of small (clinical) quantities of cell lysate and
tissue lysate (∼10–250 µg protein) [37, 38]as well as assay
speed (incubation time 2 h, phosphoimaging time 24 h). Spot
intensities can be correlated with kinase activity; however,
inference of in vivo upstream kinase activity from peptide
arrays is not straightforward. (1) Kinases are promiscuous,
multiple kinases phosphorylate the same peptide. Each spot
intensity on the array corresponds to the sum of the
accumulated kinase activities acting on the peptide immobi-
lized on the spot. Only few peptides are unique for a single
kinase and allow for direct correlation of spot intensity and
kinase activity. (2) Only a limited subset of the 518 human
protein kinases is accounted for in currently available peptide
arrays. For example, the PamChip shows an overrepresenta-
tion of EGFR signalling-related substrate peptides. (3) There
are peptides on the array for which the upstream kinases are
currently unknown (but which are phosphorylated by cell
lysate). (4) Cellular compartmentalization is lost. (5) Array-
based methods are unable to determine the actual site of
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phosphorylation, if more than a single Tyr, Ser, or Thr
residue is present in the peptide sequence. Although the
relation between kinase activity and peptide substrate spot
intensity is not 1:1, patterns of spot intensities could be
useful for pattern-based diagnostics of kinase activity.
Sikkema et al. recently demonstrated tyrosine kinase profiles
for 29 pediatric brain tumors, yielding previously reported
enhanced tyrosine kinase activity of EGFR, VEGFR, and c-
Met. In addition, peptide substrates for Src family kinases
demonstrated high phosphorylation levels. Subsequent ap-
plication of Src family kinase inhibitors PP1 and dasatinib
induced a decrease of survival in pediatric brain tumor cell
lines but not in control cell lines, suggesting therapeutic
potential for Src activity inhibition [39].
In another recent report peptide substrate chip profil-
ing of chondrosarcoma cell lines and primary cell
cultures indicated enhanced activity of the Akt/GSK3B
pathway, PDFGR, and Src family kinases [37]. It was
shown that the small-molecule kinase inhibitor dasatinib
but not imatinib decreased chondrosarcoma cell viability
at nanomolar concentrations, leading to the proposal of
using dasatinib as a therapeutic option in inoperable
patients. These recent studies illustrate the potential of
peptide substrate arrays for the identification of druggable
targets and therapy selection. Versele et al. reported an
application of the PamChip for detection of cytoplasmic
and receptor tyrosine kinase activities in cell lysates in the
presence and absence of a kinase inhibitor. In a panel of
27 cell lines and 8 xenografts, the authors were able to
identify signature peptides (16 and 8, respectively) that
resulted in clusters accurately predicting response to a
multitargeted kinase inhibitor [40].
By correlating array phosphorylation patterns with clinical
outcome, kinase peptide substrate arrays have the potential to
become a diagnostic tool for disease management. The key
factor in the design of kinase peptide substrate arrays is target
peptide selection. The choice of peptides determines the
relevance of the array. Target peptides must be selected such
that the major signalling pathways are sufficiently covered.
All nodes of the pathway should be represented by one or
more peptides. Pathway target peptides should be phosphor-
ylated exclusively by the designated upstream kinase. In
addition to peptide choice, high reproducibility and robustness
are requirements for application of kinase peptide substrate
arrays as a diagnostic platform in clinical practice. Recently, a
promising variation on the peptide substrate array has been
reported in which high resolution MS was used as the
quantitative readout. The method builds on the seminal paper
of Cutillas et al. [41], which reported on ultrasensitive and
absolute quantification of phosphoinoside 3-kinase/AKT
signal transduction by MS. In the approach termed kinase
activity assay for kinome profiling (KAYAK) 90 selected
synthetic kinase substrate peptides are pooled and incubated
in a single reaction with nanogram to microgram amounts of
cancer cell or tissue lysate [42]. Following in vitro
phosphorylation of peptides by endogenous kinases present
in the lysate, the phosphorylated peptide pool is spiked with
corresponding heavy-isotope labelled peptides, enriched by
IMAC, and identified and quantified by nanoLC–MS/MS.
The MS/MS spectra, combined with isotopically labelled
peptides, enable determination of phosphorylation site-
specific phosphorylation rates; no other method including
peptide substrate arrays is able to deliver this. The authors
foresee application of the KAYAK approach for therapy
Fig. 3 Peptide substrate array
workflow. Peptide substrate
arrays are incubated with lysate,
washed, and probed by autora-
diography or fluorescence mi-
croscopy yielding peptide
phosphorylation patterns
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selection and assessment of aberrant signalling in patient
tumors [42].
Outlook
Although small-molecule tyrosine kinase inhibitors have
changed therapeutic options in selected tumor types
considerably, these agents induce clinical benefit in a
subgroup of patients. It is of crucial importance to develop
new clinical tests to determine which patients will respond
to specific targeted agents. So far, no adequate and reliable
test to predict response is available.
As each patient has a unique genomic and proteomic
tumor profile, it is assumed that responses to targeted
agents depend on specific receptor and protein signalling
activities in tumor tissues. We therefore envision that kinase
activity profiling may be a potential clinical diagnostic tool
to predict tumor response to targeted therapy with kinase
inhibitors.
Kinase profiles of individual patients may give insight
into the deregulated signalling processes and may have
diagnostic value and aid patient therapy selection. This
application is not restricted to cancer therapy but may be
extended to other diseases with deregulated kinases. With
ten kinase inhibitors registered for treatment and an
additional few dozen under development, there is demand
for technology platforms that can faithfully map kinase
activities in patient material and the effect of TKIs ex vivo.
Chemical proteomics techniques can yield individualized
kinase passports. The kinobeads reported by Bantscheff
[26] are the first achievements in the development of a
ligand mixture capable of kinome-wide enrichment. Future
application of chemical (phospho-)proteomics may identify
differential kinases along with associated signalling com-
plexes and phosphorylation patterns for responders vs. non-
responders. The downstream targets of these differential
kinases can be translated into dedicated peptide substrate
array tests that, when validated, may be implemented in
clinical practice for therapy selection. Custom-made arrays
with clinically relevant peptides may provide an accurate
readout of tumor deregulated signalling pathways and aid in
TKI selection to provide the optimal therapy based on
patient-specific pathway activity. The currently available
therapeutic options drive development of platforms that will
enable the oncologist to select the best targeted therapy for
each individual patient.
Acknowledgments This work was supported by the VUmc-Cancer
Center Amsterdam (CRJ). The Aegon Foundation is acknowledged
for financial support (ML).
Reference
1. Ginsburg GS, Willard HF (2009) Transl Res 154:277–287
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S
(2002) Science 298:1912–1934
3. Zhang JM, Yang PL, Gray NS (2009) Nat Rev Cancer 9:28–39
4. Nolen B, Taylor S, Ghosh G (2004) Mol Cell 15:661–675
5. Vogelstein B, Kinzler KW (2004) Nat Med 10:789–799
6. Blume-Jensen P, Hunter T (2001) Nature 411:355–365
7. Daley GQ, Vanetten RA, Baltimore D (1990) Science 247:824–
830
8. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu
JM, Yang DM, Yang WK, Shen CY (2000) Oncogene 19:2739–
2744
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S,
Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N,
Dicks N, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J,
Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S,
Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C,
Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-
Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan
A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Siegler
HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R,
Stratton MR, Futreal PA (2002) Nature 417:949–954
10. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M,
Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T,
Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G,
Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian
H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ,
Durrant S, Schwarer A, Joske D, Seymour J, Grigg A, Ma D,
Arthur C, Bradstock K, Joshua D, Louwagie A, Martiat P,
Straetmans N, Bosly A, Shustik C, Lipton J, Forrest D, Walker
I, Roy DC, Rubinger M, ce-Bruckler I, Kovacs M, Turner AR,
Birgens H, Bjerrum O, Facon T, Harousseau JL, Tulliez M, Guerci
A, Blaise D, Maloisel F, Michallet M, Hossfeld D, Mertelsmann
R, Andreesen R, Nerl C, Freund M, Gattermann N, Hoeffken K,
Ehninger G, Deininger M, Ottmann O, Peschel C, Fruehauf S,
Neubauer A, Le Coutre P, Aulitzky W, Fanin R, Rosti G, Mandelli
F, Morra E, Carella A, Lazzarino M, Petrini M, Ferrini PR, Nobile
F, Liso V, Ferrara F, Rizzoli V, Fioritoni G, Martinelli G,
Ossenkoppele G, Browett P, Gedde-Dahl T, Tangen JM, Dahl I,
Odriozola J, Boluda JCH, Steegmann JL, Canizo C, Sureda A,
Diaz J, Granena A, Fernandez MN, Stenke L, Paul C, Bjoreman
M, Malm C, Wadenvik H, Nilsson PG, Turesson I, Hess U,
Solenthaler M, Russel N, Mufti G, Cavenagh J, Clark RE, Green
AR, Holyoake TL, Lucas GS, Smith G, Milligan DW, Rule SJ,
Burnett AK, Moroose R, Wetzler M, Bearden J, Brown R, Lobell
M, Cataland S, Rabinowitz I, Meisenberg B, Gabrilove J,
Thompson K, Graziano S, Emanuel P, Gross H, Cobb P, Bhatia
R, Dakhil S, Irwin D, Issell B, Pavletic S, Kuebler P, Layhe E,
Butera P, Glass J, Moore J, Grant B, Niell H, Herzig R, Burris H,
Peterson B, Powell B, Kalaycio M, Stirewalt D, Samlowski W,
Berman E, Limentani S, Seay T, Shea T, Akard L, Smith G,
Becker P, DeVine S, Hart R, Veith R, Wade J, Brunvand M, Silver
R, Kalman L, Strickland D, Shurafa M, Bashey A, Shadduck R,
Cooper S, Safah H, Rubenstein M, Collins R, Keller A, Stone R,
Tallman M, Stevens D, Pecora A, Agha M, Holmes H, Druker BJ,
Guilhot F, Larson RA, O'Brien SG, Rowe J, Schiffer CA, Buyse
M, Baccarani M, Cervantes F, Cornelissen J, Fischer T, Hochhaus
A, Hughes T, Kantarjian H, Lechner K, Nielsen JL, Reiffers J,
Rousselot P, Saglio G, Shepherd J, Simonsson B, Gratwohl A,
Goldman JM, Taylor K, Verhoef G (2003) N Engl J Med
348:994–1004
3170 S. R. Piersma et al.
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels
M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F,
Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan
MH, Simantov R, Bukowski RM (2007) N Engl J Med 356:125–
134
12. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski
RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I,
Bycott PW, Baum CM, Figlin RA (2007) N Engl J Med 356:115–
124
13. Demetri GD, van Oosterom AT, Blackstein M, Garrett C, Shah M,
Heinrich M, McArthur G, Judson I, Baum CM, Casali PG (2005)
J Clin Oncol 23:308S
14. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de
Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta
C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I,
Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D,
Bruix J (2008) N Engl J Med 359:378–390
15. Broxterman HJ, Gotink KJ, Verheul HMW (2009) Drug Resist
Updat 12:114–126
16. Johnson SA, Hunter T (2005) Nat Methods 2:17–25
17. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara
MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford
JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE,
Insko MA, Lai AG, Lelias JM, Mehta SA, Milanov ZV, Velasco
AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ (2005)
Nat Biotechnol 23:329–336
18. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE,
Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni
R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ,
Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP
(2008) Nat Biotechnol 26:127–132
19. Bantscheff M, Scholten A, Heck AJR (2009) Drug Discov Today
14:1021–1029
20. Rix U, Superti-Furga G (2009) Nat Chem Biol 5:616–624
21. Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Keri G,
Mann M, Daub H (2009) Mol Cell Proteomics 8:1751–1764
22. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M,
Schutze G, Colinge J, Bennett KL, Ellmeier WR, Valent P, Superti-
Furga G (2007) Proc Natl Acad Sci U S A 104:13283–13288
23. Rix U, Hantschel O, Duernberger G, Rix LLR, Planyavsky M,
Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Kocher
T, Superti-Furga G (2007) Blood 110:4055–4063
24. Ong SE, Schenone M, Margolin AA, Li XY, Do K, Doud MK,
Mani DR, Kuai L, Wang X, Wood JL, Tolliday NJ, Koehler AN,
Marcaurelle LA, Golub TR, Gould RJ, Schreiber SL, Carr SA
(2009) Proc Natl Acad Sci U S A 106:4617–4622
25. Fernbach NV, Planyavsky M, Muller A, Breitwieser FP, Colinge J,
Rix U, Bennett KL (2009) J Proteome Res 8:4753–4765
26. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M,
Hobson S, Mathieson T, Perrin J, Raida M, Rau C, Reader V,
Sweetman G, Bauer A, Bouwmeester T, Hopf C, Kruse U,
Neubauer G, Ramsden N, Rick J, Kuster B, Drewes G (2007) Nat
Biotechnol 25:1035–1044
27. Fischer JJ, Graebner OY, Dalhoff C, Michaelis S, Schrey AK,
Ungewiss J, Andrich K, Jeske D, Kroll F, Glinski M, Sefkow M,
Dreger M, Koester H (2010) J Proteome Res 9:806–817
28. Patricelli MP, Szardenings AK, Liyanage M, Nomanbhoy TK, Wu
M, Weissig H, Aban A, Chun D, Tanner S, Kozarich JW (2007)
Biochemistry 46:350–358
29. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL,
Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB
(2010) Nat Chem Biol 6:291–299
30. Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R,
Greff Z, Keri G, Stemmann O, Mann M (2008) Mol Cell 31:438–
448
31. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P,
Mann M (2006) Cell 127:635–648
32. Pan CP, Olsen JV, Daub H, Mann M (2009) Mol Cell Proteomics
8:2796–2808
33. Pawlak M, Schick E, Bopp MA, Schneider MJ, Oroszlan P, Ehrat
M (2002) Proteomics 2:383–393
34. Weissenstein U, Schneider MJ, Pawlak M, Cicenas J,
Eppenberger-Castori S, Oroszlan P, Ehret S, Geurts-Moespot A,
Sweep FCGJ, Eppenberger U (2006) Proteomics 6:1427–1436
35. Rubic T, Lametschwandtner G, Jost S, Hinteregger S, Kund J,
Carballido-Perrig N, Schwarzler C, Junt T, Voshol H, Meingassner
JG, Mao XH, Werner G, Rot A, Carballido JM (2008) Nat
Immunol 9:1261–1269
36. Diks SH, Kok K, O'Toole T, Hommes DW, van Dijken P, Joore J,
Peppelenbosch MP (2004) J Biol Chem 279:49206–49213
37. Schrage YM, Briaire-de Bruijn IH, de Miranda NFCC, van
Oosterwijk J, Taminiau AHM, van Wezel T, Hogendoorn PCW,
Bovee JVMG (2009) Cancer Res 69:6216–6222
38. Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman
AH, Peppelenbosch MP, Richel DJ (2008) Cancer Res 68:1213–
1220
39. Sikkema AH, Diks SH, den Dunnen WFA, ter Elst A, Scherpen
FJG, Hoving EW, Ruijtenbeek R, Boender PJ, de Wijn R, Kamps
WA, Peppelenbosch MP, De Bont ESJM (2009) Cancer Res
69:5987–5995
40. Versele M, Talloen W, Rockx C, Geerts T, Janssen B, Lavrijssen
T, King P, Gohlmann HWH, Page M, Perera T (2009) Mol Cancer
Ther 8:1846–1855
41. Cutillas PR, Khwaja A, Graupera M, Pearce W, Gharbi S,
Waterfield M, Vanhaesebroeck B (2006) Proc Natl Acad Sci U
S A 103:8959–8964
42. Kubota K, Anjum R, Yu YH, Kunz RC, Andersen JN, Kraus M,
Keilhack H, Nagashima K, Krauss S, Paweletz C, Hendrickson
RC, Feldman AS, Wu CL, Rush J, Villen J, Gygi SP (2009) Nat
Biotechnol 27:933–U98
43. Picotti P, Rinner O, Stallmach R, Dautel F, Farrah T, Domon B,
Wenschuh H, Aebersold R (2010) Nat Methods 7:43–U5
Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods 3171
